Compare LNN & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LNN | EVO |
|---|---|---|
| Founded | 1954 | 1993 |
| Country | United States | Germany |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.1B |
| IPO Year | 1988 | 2021 |
| Metric | LNN | EVO |
|---|---|---|
| Price | $123.50 | $3.34 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $136.00 | $7.00 |
| AVG Volume (30 Days) | 122.9K | ★ 253.2K |
| Earning Date | 01-08-2026 | 11-05-2025 |
| Dividend Yield | ★ 1.22% | N/A |
| EPS Growth | ★ 12.81 | N/A |
| EPS | ★ 6.78 | N/A |
| Revenue | $676,368,000.00 | ★ $887,396,457.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $6.13 | $8.52 |
| P/E Ratio | $17.85 | ★ N/A |
| Revenue Growth | ★ 11.41 | N/A |
| 52 Week Low | $106.10 | $2.84 |
| 52 Week High | $150.96 | $4.80 |
| Indicator | LNN | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 62.64 | 61.17 |
| Support Level | $117.25 | $3.10 |
| Resistance Level | $120.84 | $3.23 |
| Average True Range (ATR) | 2.93 | 0.08 |
| MACD | 0.21 | 0.04 |
| Stochastic Oscillator | 99.72 | 97.92 |
Lindsay Corp provides proprietary water management and road infrastructure products and services. It manufactures and distributes agricultural irrigation equipment through two segments: Irrigation and Infrastructure. The Irrigation segment makes center pivot, lateral move, and hose reel irrigation systems and parts. The Infrastructure segment produces barriers, crash cushions, road marking and safety equipment, and railroad signals. The majority of revenue is from the Irrigation segment. The company operates in the United States and international markets, with the majority of revenue coming from the United States.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.